What the research reports
View evidenceSURMOUNT-1 reported a mean body-weight reduction of 20.9% at week 72 in one study arm.
Image 01 / 01Research compound
Tirzepatide
Dual agonist — GIP, GLP-1 · Phase 3
Metabolic research / compoundCA$50.00
Select variant
Tirzepatide/
CA$50.00
How it works
Pharmacology work characterised tirzepatide as a fatty-acid-modified dual GIP/GLP-1 receptor agonist.
Where the evidence comes from
View evidenceTirzepatide findings shown here come from SURMOUNT-1 and cited receptor, mouse, and Phase 1 studies.
Jastreboff et al., NEJM, 2022 · PubMed · Coskun et al., Molecular Metabolism, 2018 · PubMed
What's still open
Tirzepatide body-weight findings shown here concern the cited SURMOUNT-1 population.
